KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,029 | +7.0% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $12,177 | +14.5% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $10,635 | +2.5% | 1,353 | -11.9% | 0.00% | – |
| Q4 2022 | $10,377 | -48.0% | 1,535 | +11.7% | 0.00% | -100.0% |
| Q3 2022 | $19,937 | +47.5% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $13,520 | -33.2% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $20,253 | -71.0% | 1,374 | -73.9% | 0.00% | 0.0% |
| Q4 2021 | $69,775 | -24.2% | 5,274 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $92,031 | -23.8% | 5,274 | +4.7% | 0.00% | -50.0% |
| Q2 2021 | $120,710 | -6.7% | 5,038 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $129,426 | +38.1% | 5,038 | +2.1% | 0.00% | +100.0% |
| Q4 2020 | $93,697 | +326.4% | 4,934 | +397.4% | 0.00% | – |
| Q2 2019 | $21,972 | – | 992 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |